Supplementary Fig. S1 Representative images demonstrating surfactant protein C (SPC)-terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) costaining used for quantification of alveolar epithelial cell apoptosis in bleomycin-treated wild-type (control) or transgenic mice overexpressing urokinase plasminogen activator (uPA) (CCSP-rtTA/TetO-uPA) on day 24 following 3 days of doxycycline.
Supplementary Fig. S2. Atomic force microscopy indentation of urokinase plasminogen activator (uPA) transgenic mice or littermate controls receiving intratracheal phosphate-buffered saline (PBS) or bleomycin on day 0 with doxycycline administration from days (A) 1 to 28, (B) 9 to 28, or (C) 14 to 28.
Supplementary Fig. S3 Urokinase plasminogen activator (uPA) double transgenic mice or littermates (controls) received bleomycin (1.15 U/kg) or phosphate-buffered saline (PBS) via intratracheal administration on day 0. Doxycycline was administered to mice early (day 0–14; A–D) and then discontinued or late (days 14–28; E–H). After 7 days of doxycycline administration (day 7 in the early group and day 21 in the late group), lavage fluid was obtained and inflammatory cells were quantified by flow cytometry. (A and E) Total CD45+ leukocytes. (B and F) Neutrophils. (C and G) Alveolar macrophages. (D and H) Exudate macrophages.
Supplementary Fig. S4 Average lung stiffness for individual urokinase plasminogen activator (uPA) double transgenic and control mice treated with intratracheal phosphate-buffered saline (PBS) or bleomycin on day 0 with introduction of doxycycline from days 21 to 42. For each mouse, we determined the mean ± standard deviation for all stiffness measurements obtained, and these values were used to construct this figure such that each point represents the mean of all stiffness measurements obtained for a single mouse. The error bars indicate the standard error of the mean of stiffness for all mice within the cohort.